The combination of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 inhibitors in heart failure with reduced ejection fraction patients comorbid with diabetes mellitus

Background Angiotensin receptor-neprilysin inhibitor (ARNI) and dapagliflozin were two new drugs that were proved to reduce clinical events in patients with HFrEF. However, evidence about the combination use of these two drugs in patients with both HFrEF and DM is lacking. The purpose of present study is to elucidate the clinical benefit of combining ARNI and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in this population. Methods Patients...